Glomerulonephritis associated with SARS-CoV-2 infection

Mohsen Akhavan Sepahi¹, Bhaskar VKS Lakkakula², Bijan Roshan³, Banafsheh Yalameha⁴

¹Department of Pediatric Nephrology, School of Medicine, Qom University of Medical Sciences, Qom, Iran
²Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India
³Division of Nephrology, Scripps Clinic, La Jolla, California, USA
⁴Nickan Research Institute, Isfahan, Iran

 ARTICLE INFO

Article Type: News and Views

Article History:
Received: 7 June 2020
Accepted: 29 June 2020
Published online: 24 July 2020

Keywords:
COVID-19, Nephropathy, Glomerulonephritis, kidney injury, Collapsing glomerulopathy

Implication for health policy/practice/research/medical education: Post-infectious glomerulonephritis (PIGN) can develop secondary to infections associated with bacterial, viral, fungal, protozoal, and helminthic parasites. Recently, there is a serious concern regarding the occurrence of kidney dysfunctions and subsequent acute kidney injury (AKI) among COVID-19 patients. The outcome data of COVID-19 in neonates and children demonstrated that the fatality rate is significantly higher in patients with AKI than in patients without AKI. In the current COVID-19 pandemic, few instances of glomerulonephritis (GN) in patients affected by SARS-CoV-2 have been reported. In this review, we investigated the PIGN concentrating on the COVID19-nephropathy, as well as its prevention and diagnosis strategies.

Please cite this paper as: Akhavan Sepahi M, Lakkakula BVKS, Roshan B, Yalameha B. Glomerulonephritis associated with SARS-CoV-2 infection. J Nephropharmacol. 2021;10(1):07. DOI: 10.34172/npj.2021.07.

Introduction

Post-infectious glomerulonephritis (PIGN) is one of the most common forms of glomerulonephritis (GN) (1-3). Among children, acute ‘post-streptococcal glomerulonephritis’ (APSGN) is the most common cause of PIGN, whereas viral infections are accounting for less common forms of PIGN (4,5). Further, viral infections can occur at any age (2,4). Recognizing the pattern of GN has paramount importance for causative diagnosis, treatment guidance, and prognostication of many GNs and thus frequently kidney biopsy is required (6,7). Typical APSGN and typical nephrotic syndrome in children are two major exceptions that can be initially managed without biopsy.

The immune system, with direct or indirect activation of the complement system, plays a substantial role in different forms of immune GNs such as lupus nephritis and many infectious related GN (8,9).

Although the exact cause is not known, different factors including environmental agents, immune dysregulation and genetic predisposition can lead to the formation and accumulation of immune complexes in the glomeruli (10-13). Furthermore, chronic GN is most often associated with other systemic diseases such as hypertension, diabetes mellitus, and hepatitis (14,15). Mild cases of GN do not cause any clear symptoms and may not need any treatment. The most common clinical features of GN include hypertension, macroscopic hematuria, proteinuria, and edema (16), together called nephritic syndrome. In cases where the proteinuria is severe (more than 2 g/m² of body surface area), patients may develop significant edema, hypoalbuminemia and hyperlipidemia, called nephrotic syndrome. Some other common symptoms of kidney failure due to GN include fatigue, nausea and tremulousness. In severe GN cases, confusion or coma may develop (17). Glomerular disease can clinically be asymptomatic and detected as asymptomatic proteinuria or microscopic hematuria, or may be clinically detected with overt nephrotic syndrome or nephritic syndrome or mixed nephrotic-nephritic syndrome and ultimately with progressive to chronic renal failure (3, 4).

COVID-19 and kidney injury

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel coronavirus. A series of publications have reported multiple organ dysfunction including acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) in COVID-19. Recently, there is more concern regarding AKI among COVID-19
patients as a significant risk factor for increasing morbidity and mortality (18,19). Despite lower mortality rates of COVID-19 in neonates and children, the fatality rate is significantly higher in patients with AKI than in those without AKI (20). Hematuria, proteinuria, increased blood urea nitrogen, increased serum creatinine, and AKI are common in patients with SARS-CoV-2 infection (21). Presence of viral RNA in urine of COVID-19 patients accompanied with albuminuria and hematuria is another potential link between SARS-CoV-2 infection and renal injury (22). Interestingly, a retrospective analysis of clinical data has demonstrated that the urinalysis is better in predicting kidney impairment than blood biochemistry in COVID-19 patients (23). Hence, it is important to pay more attention to the current issue and perform early diagnostic tests for kidney damage in patients with COVID-19. Angiotensin converting enzyme 2 (ACE2) the main receptor of entry of SARS-CoV-2 infection to target cells is significantly expressed in the kidney. In fact, the expression of ACE2 in the kidney is even higher than lung tissue, making renal cells prone to direct viral injury (24). SARS-CoV-2 infection can invade proximal straight tubule cells, proximal tubule, proximal convoluted tubule, and even glomerular parietal epithelial cells by ACE2 receptors and transmembrane serine protease 2 (25).

**Glomerulonephritis in COVID-19 patients**

Viral infections are well known to cause glomerular diseases. Cytomegalovirus and Epstein-Barr virus infections in adults are associated with collapsing glomerulopathy (26). In the current COVID-19 pandemic, few instances of GN in patients affected by SARS-CoV-2 have been reported. Although kidney disease in patients with COVID-19 is primarily reported in Chinese patients, a recent case report revealed presence of collapsing glomerulopathy as well as reduced renal function in an African-American woman with COVID-19 (27). Subsequent case reports of a 63-year-old black male and 46-year-old West African man also showed collapsing glomerulopathy and acute tubular necrosis that resulting from the SARS-CoV-2 effect on podocytes (28, 29). Interestingly all three case reports documented the presence of APOL1 genotypes in their patients (27-29). Presence of APOL1 high-risk genotype is the major genetic contributor to the risk for glumerulosclerosis and particularly to collapsing glomerulopathy among patients of African ancestry (30). The precise mechanism underlying COVID-19 related collapsing glomerulopathy is not known, but histopathological examinations have revealed the presence of viral particles in the cytoplasm of podocytes of patients with collapsing glomerulopathy. Alternatively, collapsing glomerulopathy could be the result of inflammation-induced podocyte injury due to cytokine release syndrome in COVID-19 patients (31).

In summary, renal tubular injury, and collapsing glomerulopathy are important complications of COVID-19 nephropathy. Direct viral effects on podocytes and/or virus-induced cytokine injury to podocytes are some of the known possible mechanisms of GN in COVID-19 patients. In addition, the presence of high-risk APOL1 genotypes increases the genetic susceptibility to collapsing glomerulopathy in COVID-19 patients of African origin. Further studies are needed to understand the SARS-CoV-2 effect on the podocyte and changes occurring in the podocytes during infection.

**Authors’ contribution**

MAS and BY prepared the primary draft. LVKSB and BR revised the manuscript. All authors read and signed the final paper.

**Conflicts of interest**

No conflict of interest.

**Ethical considerations**

Ethical issues (including data fabrication, double publication, and plagiarism) have been detected by the authors.

**Funding/Support**

None.

**References**

1. Sepah MA, Shajari A, Shakiha M, Shooshhtary FK, Salimi MH. Acute glomerulonephritis: a 7 years follow up of children in center of Iran. Acta Medica Iranica. 2011:375-8.
2. Satoskar AA, Parikh SV, Nadasdy T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol. 2020;16:32-50. doi: 10.1038/s41581-019-0178-8.
3. Rodriguez-Iturbe B, Najafian B, Silva A, Alpers CE. Acute postinfectious glomerulonephritis in children. In: Avner ED, Harmon VE, Niaudet P, Yoshikawa N, Emma F, Goldstein SL, eds. Pediatric Nephrology. 7th ed. Springer; 2016:959-81.
4. Kupin WL. Viral-Associated GN: Hepatitis B and Other Viral Infections. Clin J Am Soc Nephrol. 2017;12:1529-33. doi:10.2215/cjn.09180816.
5. Prasad N, Patel MR. Infection-Induced Kidney Diseases. Front Med (Lausanne). 2018;5:327. doi:10.3389/fmed.2018.00327.
6. Kimmel M. [Infections-associated Glomerulonephritis]. Dtsch Med Wochenschr. 2020;145:240-7. doi:10.1055/a-0974-9420.
7. Satoskar AA, Nadasdy G, Plaza JA, Sedmak D, Shidham G, Hebert L, et al. *Staphylococcus* Infection-Associated Glomerulonephritis Mimicking IgA Nephropathy. Clin J Am Soc Nephrol. 2006;1:1179-86. doi: 10.2215/cjn.01030306.
8. Bhaskar LVKS, Nagaraju GP. Clinical and Immunogenetic Aspects of Systemic Lupus Erythematosus. 2019;39:343-60.
Glomerulonephritis associated-SARS-CoV-2

doi: 10.1615/CritRevImmunol.2020033247.
9. Zhang Y, Geng X, Tan Y, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127:110195. doi:10.1016/j.biopha.2020.110195.
10. Olaru F, Döbel T, Lonsdorf AS, Oehrl S, Maas M, Enk AH, et al. Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. JCI Insight. 2018;3:e96492. doi:10.1172/jci.insight.96492.
11. Zhang W, Chen X, Shi S, Wei R, Wang J, Yamanaka N, et al. Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril. Nephrol Dial Transplant. 2005;20:892-901. doi:10.1093/ndt/gfh652.
12. Nast CC. Infection-related glomerulonephritis: changing demographics and outcomes. Adv Chronic Kidney Dis. 2012;19:68-75. doi: 10.1053/j.ackd.2012.02.014.
13. Nasr SH, Kopp JB. COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney Int Rep. 2020;5(6):759-761. doi: 10.1016/j.ekir.2020.04.030.
14. Yoo J-H, Lee J-H, Yoon J-H, Lee M, Lee DH, Cho Y, et al. Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in Korean patients with chronic hepatitis B. Gastroenterol Res Pract.. 2015;2015:126532. doi: 10.1155/2015/126532.
15. Magooon S, Bichu P, Malhotra V, Alhashimi F, Hu Y, Khanna S, Berhanu K. COVID-19-related glomerulopathy: a report of 2 cases of collapsing focal segmental glomerulosclerosis. Kidney Med. 2020 Jun 7. doi: 10.1016/j.xkme.2020.05.004.
16. Baldwin DS. Chronic glomerulonephritis: nonimmunologic mechanisms of progressive glomerular damage. Kidney Int. 1982;21:109-20. doi:10.1038/ki.1982.17.
17. Arnold R, Issar T, Krishnan AV, Russel BA. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis. 2016;5:2048004016677687. doi:10.1177/2048004016677687.
18. Battle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31:1380-1383. doi:10.1681/ASN.2020040419.
19. Zhang Y, Xiao M, Zhang S. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38.
20. Xu S, Fu L, Fei J, Xiang H-X, Xiang Y, Tan Z-X, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv. 2020:2020.03.24.20042408. doi: 10.1101/2020.03.24.20042408.
21. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020. doi:10.1016/j.kint.2020.03.005.
22. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of COVID-19 patients. medRxiv. 2020:2020.02.08.20021212. doi:10.1101/2020.02.08.200212 12.
23. Zhou H, Zhang Z, Fan H, Li J, Li M, Dong Y, et al. Urinalysis, but not blood biochemistry, detects the early renal-impairment in patients with COVID-19. medRxiv. 2020:2020.04.03.20051722. doi:10.1101/2020.04.03.200517 22.
24. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. Current problems in cardiology. 2020;45:100618-. doi:10.1016/j.cpcardiol.2020.100618.
25. He Q, Mok TN, Yun L, He C, Li J, Pan JH. Single cell RNA sequencing analysis of human kidney reveals the presence of ACE2 receptor: a potential pathway of COVID-19 Infection. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3544810.
26. Wenderfer SE. Viral-associated glomerulopathies in children. Pediatr Nephrol. 2015;30:1929-38. doi: 10.1007/ s00467-015-3057-y.
27. Larsen CP, Bourne TD, Wilson JD, Saqqa O, Sharshir MdA. Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19). Kidney Int Rep. 2020;5(6):935-9. doi:10.1016/j.ekir.2020.04.002.
28. Kissling S, Rotman S, Gerber C, Halfon M, Lamoth F, Comte D, et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020. doi:10.1016/j.kint.2020.04.006.
29. Peleg Y, Kudose S, D’Agati V, Siddall E, Ahmad S, Kisselev S, et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020;5(6):940-5. doi: 10.1016/j.ekir.2020.04.017.
30. Jhaveri KD, Meir LR, Flores Chang BS, et al. Thoracic microangiopathy in a patient with COVID-19. Kidney Int. 2020. doi:10.1016/j.kint.2020.05.025.
31. Nasr SH, Kopp JB. COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney Int Rep. 2020;5:759-61. doi: 10.1016/j.ekir.2020.04.030.